New Propargyloxy Derivatives of Galangin, Kaempferol and Fisetin-Synthesis, Spectroscopic Analysis and In Vitro Anticancer Activity on Head and Neck Cancer Cells

Cells. 2023 Sep 15;12(18):2288. doi: 10.3390/cells12182288.

Abstract

Head and neck cancer (HNC) therapy is limited; therefore, new solutions are increasingly being sought among flavonoids, which exhibit numerous biological properties, including potential anticancer activity. However, because they are mostly insoluble in water, are unstable and have low bioavailability, they are subjected to chemical modification to obtain new derivatives with better properties. This study aimed to synthesize and analyze new propargyloxy derivatives of galangin, kaempferol and fisetin, and to evaluate their anticancer activity against selected HNC cell lines. The obtained derivatives were assessed by spectroscopic analysis; next, their anticancer activity was evaluated using a flow cytometer and real-time cell analysis. The results showed that only the fisetin derivative was suitable for further analysis, due to the lack of crystal formation of the compound. The fisetin derivative statistically significantly increases the number of cells in the G2/M phase (p < 0.05) and increases cyclin B1 levels. A statistically significant increase in the number of apoptotic cells after being exposed to the tested compound was also observed (p < 0.05). The data indicate that the obtained fisetin derivative exhibits anticancer activity by affecting the cell cycle and increasing apoptosis in selected HNC lines, which suggests its potential use as a new medicinal agent in the future.

Keywords: anticancer; apoptosis; cyclin; flavonol; flow cytometry; head and neck cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Flavonoids / pharmacology
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Kaempferols* / pharmacology

Substances

  • fisetin
  • galangin
  • Kaempferols
  • Flavonoids

Grants and funding

This research was funded by Medical University of Silesia, grant number PCN-1-028/N/2/I.